4
Changes in Ownership
Aclaris Therapeutics, Inc. Filed Acc 0001415889-25-002939
Chief Financial Officer gave up 5,816 shares (to pay taxes)
- Chief Financial Officer acquired 14,750 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Balthaser Kevin Chief Financial Officer | 2025-02-01 | Option exercise | +14,750 | 95,676 | D | ||
| Balthaser Kevin Chief Financial Officer | 2025-02-01 | Shares withheld for taxes | −5,816 | $2.48 | $14,424 | 89,860 | D |
| Derivatives | |||||||
| Balthaser Kevin Chief Financial Officer | 2025-02-01 | Option exercise · Restricted Stock Units | −14,750 | 44,250 | D | ||
| Balthaser Kevin Chief Financial Officer | 2025-02-03 | Grant or award · Restricted Stock Units | +88,100 | 88,100 | D | ||
| Balthaser Kevin Chief Financial Officer | 2025-02-03 | Grant or award · Employee Stock Option (Right to Buy) | +308,200 | 308,200 | D | ||
Loading xslF345X05/form4-02042025_040204.xml…